Close

UPDATE: Canaccord Genuity Starts Acorda Therapeutics, Inc. (ACOR) at Hold

April 17, 2014 6:51 AM EDT
Get Alerts ACOR Hot Sheet
Price: $11.91 --0%

Rating Summary:
    4 Buy, 12 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 10
Join SI Premium – FREE
(Updated - April 17, 2014 8:43 AM EDT)

Canaccord Genuity initiated coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Hold rating and a price target of $37.00.

Analyst John Newman said, "Phase 3 dalfampridine data in stroke to drive shares: We believe interim data for once-daily fampridine post-stroke should drive value but await visibility given the recent clinical delay. Positive Phase 2 data for dalfampridine-QD suggest Phase 3 data will be positive, despite the change to a two-minute timed walk endpoint. We believe dalfampridine expansion into post-stroke walking deficits could add $357M in peak revenues, with operating leverage based on Acorda’s existing neurology salesforce."

For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.

Shares of Acorda Therapeutics, Inc. closed at $35.34 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Canaccord Genuity